Δευτέρα 12 Ιουνίου 2017

Marker in Prostate Cancer Fails to Predict Response to PARP Inhibition

This video examines clinical and genomics data from the NCI 9012 trial, which studied abiraterone combined with a PARP inhibitor in patients with metastatic castration-resistant prostate cancer. (Source: CancerNetwork)

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tdYzkt
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις